{"id":33891,"date":"2025-05-22T00:41:18","date_gmt":"2025-05-21T16:41:18","guid":{"rendered":"https:\/\/flcube.com\/?p=33891"},"modified":"2025-05-22T00:41:19","modified_gmt":"2025-05-21T16:41:19","slug":"shandong-buchang-pharmaceuticals-partners-with-fbc-for-mf59-adjuvant-rd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33891","title":{"rendered":"Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&amp;D"},"content":{"rendered":"\n<p>China-based Shandong Buchang Pharmaceuticals Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/603858:SHA\">SHA: 603858<\/a>) announced plans to enter into an Entrusted R&amp;D Agreement with compatriot firm FBC (Shanghai) Pharmaceutical Technology Co., Ltd. The agreement relates to the MF59 emulsion adjuvant, which Buchang Pharma is developing as part of a Category II vaccine.<\/p>\n\n\n\n<p><strong>Agreement Details<\/strong><br>Under the accord, Buchang Pharma, which is developing a vaccine with MF59 as the adjuvant, will entrust FBC Pharma to conduct partial research on MF59 during the Investigational New Drug (IND) and New Drug Application (NDA) stages. Buchang Pharma will pay RMB 1.2 million (USD 166,378) and RMB 300,000 (USD 41,597) during the respective stages.<\/p>\n\n\n\n<p><strong>Commercialization Stage<\/strong><br>In the commercialization stage, Buchang Pharma will be responsible for the production, self-inspection, batch issuance application, and commercialization activities of the vaccine. Buchang Pharma will also pay a maximum sales commission of RMB 20 million (USD 2.8 million) to FBC Pharma.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/603858_20250521_PTFU.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603858_20250521_PTFU.\"><\/object><a id=\"wp-block-file--media-c71e52ff-2067-4457-b424-3ebf75df17fe\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/603858_20250521_PTFU.pdf\">603858_20250521_PTFU<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/603858_20250521_PTFU.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c71e52ff-2067-4457-b424-3ebf75df17fe\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33894,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[280,19,4087,1103],"class_list":["post-33891","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-buchang-pharmaceuticals","tag-cro-cmo-cdmo","tag-fbc-pharmaceutical-technology","tag-sha-603858"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&amp;D - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted R&amp;D Agreement with compatriot firm FBC (Shanghai) Pharmaceutical Technology Co., Ltd. The agreement relates to the MF59 emulsion adjuvant, which Buchang Pharma is developing as part of a Category II vaccine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33891\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&amp;D\" \/>\n<meta property=\"og:description\" content=\"China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted R&amp;D Agreement with compatriot firm FBC (Shanghai) Pharmaceutical Technology Co., Ltd. The agreement relates to the MF59 emulsion adjuvant, which Buchang Pharma is developing as part of a Category II vaccine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33891\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-21T16:41:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T16:41:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2114.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33891#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33891\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&amp;D\",\"datePublished\":\"2025-05-21T16:41:18+00:00\",\"dateModified\":\"2025-05-21T16:41:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33891\"},\"wordCount\":159,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33891#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2114.webp\",\"keywords\":[\"Buchang Pharmaceuticals\",\"CRO \\\/ CMO \\\/ CDMO\",\"FBC Pharmaceutical Technology\",\"SHA: 603858\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33891#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33891\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33891\",\"name\":\"Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&amp;D - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33891#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33891#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2114.webp\",\"datePublished\":\"2025-05-21T16:41:18+00:00\",\"dateModified\":\"2025-05-21T16:41:19+00:00\",\"description\":\"China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted R&D Agreement with compatriot firm FBC (Shanghai) Pharmaceutical Technology Co., Ltd. The agreement relates to the MF59 emulsion adjuvant, which Buchang Pharma is developing as part of a Category II vaccine.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33891#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33891\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33891#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2114.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2114.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&D\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33891#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&amp;D\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&amp;D - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted R&D Agreement with compatriot firm FBC (Shanghai) Pharmaceutical Technology Co., Ltd. The agreement relates to the MF59 emulsion adjuvant, which Buchang Pharma is developing as part of a Category II vaccine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33891","og_locale":"en_US","og_type":"article","og_title":"Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&amp;D","og_description":"China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted R&D Agreement with compatriot firm FBC (Shanghai) Pharmaceutical Technology Co., Ltd. The agreement relates to the MF59 emulsion adjuvant, which Buchang Pharma is developing as part of a Category II vaccine.","og_url":"https:\/\/flcube.com\/?p=33891","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-21T16:41:18+00:00","article_modified_time":"2025-05-21T16:41:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2114.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33891#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33891"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&amp;D","datePublished":"2025-05-21T16:41:18+00:00","dateModified":"2025-05-21T16:41:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33891"},"wordCount":159,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33891#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2114.webp","keywords":["Buchang Pharmaceuticals","CRO \/ CMO \/ CDMO","FBC Pharmaceutical Technology","SHA: 603858"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33891#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33891","url":"https:\/\/flcube.com\/?p=33891","name":"Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&amp;D - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33891#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33891#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2114.webp","datePublished":"2025-05-21T16:41:18+00:00","dateModified":"2025-05-21T16:41:19+00:00","description":"China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted R&D Agreement with compatriot firm FBC (Shanghai) Pharmaceutical Technology Co., Ltd. The agreement relates to the MF59 emulsion adjuvant, which Buchang Pharma is developing as part of a Category II vaccine.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33891#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33891"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33891#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2114.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2114.webp","width":1080,"height":608,"caption":"Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&D"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33891#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&amp;D"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2114.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33891"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33891\/revisions"}],"predecessor-version":[{"id":33895,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33891\/revisions\/33895"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33894"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}